Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study Free with registration until Dec 15, 2025

Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study Free with registration until Dec 15, 2025 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00594-7/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esmoasia25&_hsenc=p2ANqtz-9mEwLKB56iQED-WH0i2aVQyssH8uMXU4zILOJnnTljHukqJ_jFfm8Sd1Ztzpmi0K_NzeMlUwPLXYeX08K8iRSIkcTuSw&_hsmi=393141221&utm_content=393141221&utm_source=hs_email